Treatment of Osteomyelitis in Adults with Bone Culture Positive for Methicillin-Resistant Staphylococcus aureus (MRSA)
This protocol addresses adult patients with osteomyelitis in whom bone culture has confirmed methicillin-resistant Staphylococcus aureus (MRSA) as the causative organism.
The identification of MRSA on bone culture is the critical decision point: the choice of antibiotic therapy is specific to this culture result. Standard agents used for methicillin-susceptible organisms are not effective here, and a targeted approach is required from the outset of treatment.
Treatment Approach — Partial Overview
Management is guided by the confirmed MRSA culture result and centres on targeted antibiotic therapy with a primary agent selected for activity against this organism. For patients with a relevant allergy to the primary agent, the protocol defines alternative antibiotic options.
The complete regimen — including specific agents, doses, frequencies, routes, and duration — is available in the full structured protocol below.
References
- The choice of antibiotic therapy is specific to the culture results listed in Table 3.
- Initial Antibiotic Therapy for Osteomyelitis in Adults
- Staphylococcus aureus, methicillin resistant
- Vancomycin, 15 to 20 mg per kg per dose IV every 8 to 12 hours
- For patients allergic to vancomycin:
- Linezolid (Zyvox), 600 mg IV every 12 hours
- Rifampin, 600 mg daily
View source ↗